PHC Holdings Signs Agreement to Acquire Thermo Fisher Scientific's Anatomic Pathology Business

Wednesday, Jan 30, 2019

PHC Holdings Corporation (Headquarters: Tokyo, Japan, hereinafter PHCHD) today announced the signing of a definitive agreement with Thermo Fisher Scientific Inc. (NYSE: TMO) (hereinafter referred to as after Thermo Fisher), a world leader in science, aiming to acquire Thermo Fisher's anatomical pathology business for about 1.14 billion USD.

Thermo Fisher's Anatomic Pathology Company is a leading supplier of microscope slides, instruments and consumables in the industry and is part of Thermo Fisher's Specialty Diagnostics segment in the US, Europe and China. with about 1200 employees.

PHCHD is a global healthcare company offering value-added products and services for diabetes care, diagnostics, life sciences and medical informatics. In order to accelerate its commercial growth, PHCHD will expand its business portfolio through the acquisition of Thermo Fisher's business.

Hidehito Kotani, Ph.D. and CEO of PHCHD commented, "We are pleased to have signed this agreement with Thermo Fisher Scientific. Their anatomical pathology business has grown steadily thanks to their strong customer base in international hospital markets, particularly in the United States. It is a strong company with good growth potential and we believe it will create value for our stakeholders as part of our growing portfolio of diagnostics and healthcare. "

PHCHD anticipates that the transaction will be completed in the second half of 2019, subject to customary closing conditions and applicable regulatory approvals.



Other News